[Nitrates in the treatment of congestive heart failure]. 1993

A L Bordalo e Sá
UTIC-Arsénio Cordeiro, Hospital de Santa Maria, Lisboa.

In this revision article, after referring the mechanisms of action of nitrates in the relief of heart failure symptoms, the author presents the results of the controlled studies which show the beneficial effect of the nitrates on heart failure symptoms and mortality. The results of the therapy with nitrates are compared to other heart failure therapies, such as the administration of the angiotensin conversion enzyme (ACE) inhibitors. In spite of the highly favourable results regarding mortality shown by the latest studies with ACE inhibitors, the nitrates still occupy an essential place in the therapy of patients with heart failure, since they have the advantage of a much faster onset of action and are more effective in relieving symptoms than ACE inhibitors. Ancient problems of controversial clinical significance are focused such as resistance and tolerance to nitrates, its clinical implications, and possible methods for prevention of nitrate tolerance and resistance are reviewed. Finally, the author suggests some dosage and administration routes of the nitrates in heart failure, giving attention to particular clinical groups, namely the elderly and other special cases, and their adverse events.

UI MeSH Term Description Entries
D009566 Nitrates Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical. Nitrate
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A L Bordalo e Sá
May 1996, The American journal of cardiology,
A L Bordalo e Sá
March 1989, The Medical clinics of North America,
A L Bordalo e Sá
June 1994, Cardiovascular drugs and therapy,
A L Bordalo e Sá
July 1985, The American journal of cardiology,
A L Bordalo e Sá
November 1987, The American journal of cardiology,
A L Bordalo e Sá
July 1979, Modern concepts of cardiovascular disease,
A L Bordalo e Sá
January 1980, Heart & lung : the journal of critical care,
A L Bordalo e Sá
January 1993, Coronary artery disease,
Copied contents to your clipboard!